BRIM Biotechnology, Inc. (TPE:6885)
Taiwan · Delayed Price · Currency is TWD 22.40
-0.40 (-1.75%)
At close: May 8, 2026
BRIM Biotechnology Revenue
In the year 2025, BRIM Biotechnology had annual revenue of 5.49M TWD with 1,548.65% growth. BRIM Biotechnology had revenue of 2.59M in the quarter ending December 31, 2025, with 868.16% growth.
Revenue
5.49M
Revenue Growth
+1,548.65%
P/S Ratio
543.53
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.49M | 5.16M | 1,548.65% |
| Dec 31, 2024 | 333.00K | 243.00K | 270.00% |
| Dec 31, 2023 | 90.00K | -436.00K | -82.89% |
| Dec 31, 2022 | 526.00K | 166.00K | 46.11% |
| Dec 31, 2021 | 360.00K | -90.41M | -99.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Syngen Biotech | 2.07B |
| Apex Biotechnology | 1.94B |
| SYN-TECH Chem. & Pharm. | 1.26B |
| Chunghwa Chemical Synthesis & Biotech | 804.88M |
| Genovate Biotechnology | 492.41M |
| HeXun Biosciences | 293.23M |
| BioGend Therapeutics | 229.81M |
| Intech Biopharm | 107.53M |